# A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer

> **NCT05787561** · PHASE2 · RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 40 (estimated)

## Conditions studied

- Mesonephric Gynecologic Cancer

## Interventions

- **DRUG:** Avutometinib (VS-6766)
- **DRUG:** Defactinib

## Key facts

- **NCT ID:** NCT05787561
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-15
- **Primary completion:** 2027-03
- **Final completion:** 2027-03
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-04-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05787561

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05787561, "A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05787561. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*